Mechanistically, METTL16-mediated m6A modification reduces MXD4 mRNA stability, leading to decreased MXD4 protein levels, which indirectly activates the MYC–MAX complex and downstream target gene expression, thereby promoting AML cell proliferation and survival. The gene discussed is METTL16; the disease is acute myeloid leukemia.